Skip to main content
Federal Circuit· 6/12/2015

Ariosa Diagnostics, Inc. v. Sequenom, Inc.

Citations

  • 788 F.3d 1371
  • 115 U.S.P.Q. 2d (BNA) 1152
  • 2015 U.S. App. LEXIS 9855
  • 2015 WL 3634649

How courts have described this case

Verbatim parenthetical descriptions written by other courts when citing this decision. Ranked by citation-network relevance.

  • holding that utilizing routine and convention methods for amplifying and detecting cfflDNA, a natural phenomenon, was insufficient to render the claims at issue patent eligible
  • holding ineligible the claimed process for using PCR to amplify cff-DNA in a sample before detecting it
  • finding that method claims that began and ended with a natural phenomenon were directed to naturally occurring matter
  • finding that the claims at issue were not patent eligible because they were directed to naturally occurring phenomena (step one
  • rejecting the argument that a newly discovered natural phenomenon can supply an inventive concept
  • invalidating claims to methods of detecting cffDNA in maternal serum or plasma that encompassed any diagnosis of any disease

Source: CourtListener parenthetical corpus (CC0).

Judges: Reyna, Linn, Wallach

Read full opinion on CourtListener

Cited by

57 cases in this archive cite this case; the 20 most cited are listed.

Cites

11 cases in this archive are cited by this case.

Other cases named Ariosa Diagnostics, Inc. v. Sequenom, Inc.

3 other CourtListener records share this case name.

Sourced from CourtListener / Free Law Project (CC0).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.